Navigating Frontline Treatment Decisions in Metastatic Pancreatic Cancer

Shubham Pant, MD, discusses data from the phase 3 NAPOLI 3 trial supporting NALIRIFOX as a potent frontline regimen for metastatic pancreatic cancer.

Raji Shameem, MD, discusses first-line treatment planning for pancreatic adenocarcinoma including clinical trial eligibility alongside standard chemotherapy options.

Raji Shameem, MD, discusses the continuing evolution of the frontline treatment landscape of metastatic pancreatic cancer.

Zev A. Wainberg, MD, discusses current available frontline chemotherapy regimens for patients with metastatic pancreatic cancer.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Zev A. Wainberg, MD, MSc, outlines factors informing his choice between standard frontline chemotherapy regimens in metastatic pancreatic cancer.

Dong Kim, MD, discusses the evolving decision-making process for selecting a frontline chemotherapy regimen in pancreatic cancer.

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Efrat Dotan, MD, discusses gemcitabine and nab-paclitaxel in treatment-naive, older patients with pancreatic cancer.

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Raji Shameem, MD, discusses the significance of the FDA approval of NALIRIFOX and first-line treatment selection in metastatic pancreatic cancer.